Literature DB >> 21506630

The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.

Volker Wilckens1, Klaus Kannengiesser, Kerstin Hoxhold, Christian Frenkel, Torsten Kucharzik, Christian Maaser.   

Abstract

INTRODUCTION: With immunosuppressive therapy of inflammatory bowel diseases (IBDs) becoming more aggressive, the risk of serious infections is increasing. Guidelines are currently being modified in respect to advisable immunizations. The aim of this study was to evaluate the immunization habits of IBD patients in daily practice before the implementation of specific guidelines.
METHODS: Hundred and two consecutive patients attending the outpatients IBD clinic at our hospital were interviewed regarding their immunization record. In addition, hepatitis B and C, HIV, and cytomegalovirus (CMV) serostatus were measured following a European Crohn's and Colitis Organization (ECCO) consensus.
RESULTS: Hundred and two patients with IBD have been included; of these 72% were taking steroids, 46% azathioprine, and 23% anti-TNF medication. Nineteen percent of the study population had been vaccinated against influenza, 3% against pneumoccous pneumonia, 22% against hepatitis B, 5% against varizella, 55% against rubella/mumps/measles, and 63% against tetanus. Of those who had traveled, 9% had been vaccinated for hepatitis A and 1% for yellow fever. Reasons given for not being vaccinated were not being aware of the necessity in 45% of those questioned and being afraid in 17%. While no patient was tested positive for hepatitis B, HIV, and CMV-IgM, one female patient was tested positive for hepatitis C (antibody and PCR positive, genotype I), which was unknown at that point.
CONCLUSION: Considering the high number of our patients receiving immunosuppressive therapy, the immunization record is alarmingly poor supporting the need for optimized IBD guidelines, better awareness, and patient education. In addition, the screening for chronic infections appears to be useful as suggested by the positive finding of a previously unknown hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506630     DOI: 10.3109/00365521.2011.574734

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  17 in total

1.  [Insufficient tetanus vaccination protection in psoriasis and systemic immunosuppression : Results of a retrospective investigation of 101 patients].

Authors:  W Sondermann; L Leister; N Rompoti; J Dissemond; J Klode; A Körber
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

2.  Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.

Authors:  Katrine R Christensen; Casper Steenholdt; Sine S Buhl; Mark A Ainsworth; Ole Ø Thomsen; Jørn Brynskov
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 3.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

Review 4.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 5.  Preventing infective complications in inflammatory bowel disease.

Authors:  Justine Mill; Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 7.  Vaccination strategies in patients with IBD.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

8.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

9.  Prevention of infection caused by immunosuppressive drugs in gastroenterology.

Authors:  Katarzyna Orlicka; Eleanor Barnes; Emma L Culver
Journal:  Ther Adv Chronic Dis       Date:  2013-07       Impact factor: 5.091

Review 10.  Vaccination in Patients with Inflammatory Bowel Diseases.

Authors:  Christine N Manser; Michel H Maillard; Gerhard Rogler; Philipp Schreiner; Florian Rieder; Silja Bühler
Journal:  Digestion       Date:  2020-01-22       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.